Effect of  a comprehensive heart failure treatment program on left ventricular ejection fraction and six-minute walk distance in heart failure patients with reduced ejection fraction at Lampang Hospital

Boonyapiphat T; Udol K

Authors

Boonyapiphat T Department of Medicine, Lampang Hospital, Thailand
Udol K Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Keywords:

heart failure, comprehensive heart failure treatment, heart failure clinic, left ventricular ejection fraction, six-minute walk distance, multidisciplinary team

Abstract

Objectives Patients with chronic heart failure have excessively high mortality and readmission rates and a poor quality of life. This single group, pre-post intervention study aimed to evaluate the effects of a comprehensive heart failure treatment program on left ventricular ejection fraction (LVEF) and the six-minute walk distance in patients diagnosed with heart failure with reduced ejection fraction (HFrEF).

Methods Patients with HFrEF participated in a comprehensive, on-going heart failure treatment program at Lampang Hospital. The program focuses on guideline-directed medical therapy (GDMT) for heart failure, cardiac rehabilita- tion, and health education for patients and caregivers regarding self-care and self-adjustment of diuretics. The program was managed by a multidisciplinary team comprised of cardiologists, heart failure nurses, pharmacists and physical therapists. LVEF was evaluated at baseline and at 6- and 9-month follow-ups. Six-minute walk distance was assessed at baseline and at 12±3 month follow-ups.

Results Sixty-one HFrEF patients were included. After participation in the program, there was significant improve- ment in LVEF (mean LVEF 27% before participation vs. 47% at 6- and 9 month follow-ups, p<0.001) and six-minute walk distance (mean 313 m before participation vs. 357 m at 12±3 month follow-ups, p<0.001). Patients also reported improved quality of life and New York Heart Association functional class.

Conclusions In patients with HFrEF, participation in a comprehensive heart failure treatment program may lead to improvement in LVEF and six-minute walk distance.

References

1.Laothavorn P, Hengrussamee K, Kanjanavanit R, Moleerergpoom W, Laorakpongse D, Pachirat O, et al. Thai Acute Decompensated Heart Failure Registry (Thai ADHERE). CVD Prev Control. 2010;5:89-95.

2.Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99-104.

3.Gonseth J, Guallar-Castillón P, Banegas JR, Rodríguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004;25:1570-95.

4.Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J. 2005;149:722-9.

5.Gwadry-Sridhar FH, Flintoft V, Lee DS, Lee H, Guyatt GH. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med. 2004;164:2315-20.

6.Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358-67.

7.Boonyapiphat T, Udol K. Effect of a comprehensive heart failure treatment program on heart failure readmissions and quality of life. Thai Heart J. 2007; 20: 117-24.

8.Wongwantanee S, Kiatjaroensin S, Dowmanee P, Jaratpatanawong C, Kumti T. [Effectiveness of heart failure clinic care in Rayong hospital]. J Prapokklao Hosp Clin Med Educat Center. 2010;27:222-233. Thai.

9.Chaikitamnuaychok S, Unburee J. [Development of a transitional care programme for heart failure patients at Kamphaengphet Hospital]. Thai J Nurs Counc. 2015;30:45-56. Thai.

10.Kanoksilp A, Hengrussamee K, Wuthiwaropas P. A comparison of one-year outcome in adult patients with heart failure in two medical setting: heart failure clinic and daily physician practice. J Med Assoc Thai. 2009;92:466-70.

11.SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.

12.Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6.

13.Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55.

14.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.

15.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.

16.Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17.

17.The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-200.

18.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

19.Levine TB, Levine AB, Bolenbaugh J, Green PR. Reversal of heart failure remodeling: is it maintained? Clin Cardiol. 2003;26:419-23.

20.Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431-8.

21.Cleland JG, Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death? Br Heart J. 1994;72(3 Suppl):S81-6.

22.Van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature .J Cardiovasc Pharmacol. 1998;32 Suppl 1:S31-5.

23.Abdulla J, Abildstrom SZ, Christensen E, Kober L, Torp-Pedersen C. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail. 2004;6:927-35.

24.Abdulla J, Køber L, Christensen E,Torp-Pedersen C. Effect of beta-blocker therapy on functional status in patients with heart failure – a meta-analysis.Eur J Heart Fail.2006;8:522-31